20/20 Biolabs, Inc.

AIDX Nasdaq CIK: 0001139685

Company Information

Industry Services-Testing Laboratories
SIC Code 8734
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 9430 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Mailing Address 15810 GAITHER ROAD, SUITE 235, GAITHERSBURG, MD, 20877
Phone 2404536339
Fiscal Year End 1231
EIN 522272107

Financial Overview

FY2025

$4.14M
Total Assets
$4.16M
Total Liabilities
$1.78M
Cash & Equivalents
$-0.76
EPS

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 31, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 10, 2026 View on SEC
SCHEDULE 13D Beneficial ownership report (>5%) March 10, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 25, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
3 Initial insider ownership report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC

IPO Filings

S-1 December 12, 2025
  • Focus on developing advanced diagnostic tests for early disease detection, particularly in infectious diseases and certain types of cancer.
  • Demonstrating steadily increasing year-over-year sales and expanding into new markets.
View Analysis

Annual Reports

10-K March 31, 2026
  • Cancer testing revenue surged 457% from 2022 to 2025.
  • Proprietary AI trained on 2.5 million health records achieves 85% detection accuracy.
View Analysis

Related Companies

Companies in the same industry (SIC: 8734)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.